STALICLA will present new data from the biological characterization of a novel DEPI-identified endophenotype within Autism Spectrum Disorder (ASD): ASD Phenotype 1 (ASD-Phen1) at The BRAIN Foundation Synchrony 2020 conference Dec. 12th 2020
STALICLA is now enrolling patients with ASD Phenotype 1 in the first interventional trial with STP1 in this biologically-defined subpopulation (NCT04644003). STALICLA is also conducting two observational studies (NCT04600882 and NCT04273087) to identify new subgroups of patients within the autism spectrum.
Tackling the challenges of precision medicine in Neuropsychiatry
Scaling Tech into Successful Companies